Search

Displaying results 81 - 90 of 760 in total
  1. Drug

    Dimetacrine

    go.drugbank.com/drugs/DB08996
    ApprovedWithdrawn

    Dimetacrine is a tricyclic antidepressant (TCA) with imipramine-like effects used in Europe for the treatment of depression. Dimetacrine is no longer used in Japan.

  2. Drug

    Docusate

    go.drugbank.com/drugs/DB11089
    Approved

    Still docusate is available in over-the-counter products as a common laxative.

    Products: Euro-docusate C
  3. Drug

    Dienogest

    go.drugbank.com/drugs/DB09123
    ApprovedInvestigational

    It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself. … In Europe, Australia, Malaysia, Singapore and Japan, dienogest single therapy is an approved treatment for endometriosis to alleviate painful symptoms of endometriosis and reduce endometriotic lesions

  4. Drug

    Ulipristal

    go.drugbank.com/drugs/DB08867
    ApprovedInvestigational

    Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic a...

  5. Drug

    Bismuth subgallate

    go.drugbank.com/drugs/DB13909
    Approved

    Possessing protective effects on the gastric mucosa, strong astringent effects, and not as yet elucidated antimicrobial and hemostatic actions, bismuth subgallate is most commonly available as an over-the-counter

  6. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg.

  7. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591]

  8. Drug

    Sumatriptan

    go.drugbank.com/drugs/DB00669
    ApprovedInvestigational

    [L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.

  9. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients with Alagille syndrome:[L43547] it was granted marketing authorization in Europe

  10. Drug

    Leflunomide

    go.drugbank.com/drugs/DB01097
    ApprovedInvestigational

    Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.